Effects of rosiglitazone and aspirin on experimental model of induced type 2 diabetes in rats: focus on insulin resistance and inflammatory markers

Journal of Diabetes and its Complications

Volumn 24, Issue 3, 2010, Pages 168-178

  Abdin, Amany A ^a   Baalash, Amal A ^a   Hamooda, Hala E ^a  

^a TANTA UNIVERSITY   (Egypt)

Author keywords

Aspirin; Inflammatory markers; Insulin resistance; Rosiglitazone; Type 2 diabetes

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FATTY ACID; GLUCOSE; INSULIN; INTERLEUKIN 6; ROSIGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD GLUCOSE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIETARY FATS; DRUG THERAPY, COMBINATION; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; RATS; THIAZOLIDINEDIONES;

EID: 77953134196     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2009.01.005     Document Type: Article

References (73)

1. American Diabetic Association. Consensus development conference on insulin resistance: 5-6 November 1997. Diabetes Care 21 (1998) 310-314
2. Arnalich F., Hernanz A., Lopez-Maderuelo D., Camacho J., Madero R., Vazquez J.J., and Montiel C. Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Hormone and Metabolic Research 32 (2000) 407-412
3. Baldeweg S.E., Golay A., Natali A., Balkau B., Del Prato S., and Coppack S.W. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Journal of Clinical Investigation 30 (2000) 45-52
4. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., Vidal H., and Hainque B. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. Journal of Clinical Endocrinology and Metabolism 85 9 (2000) 3338-3342
5. Bdarham D., and Trinder P. Enzymatic determination of glucose. Analyst 97 (1972) 142-145
6. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46 1 (1997) 3-10
7. Bratusch-Marrain P.R., Vierhapper H., Komjati M., and Waldhausl W.K. Acetyl-salicylic acid impairs insulin-mediated glucose utilization and reduces insulin clearance in healthy and non-insulin-dependent diabetic man. Diabetologia 28 9 (1985) 671-676
8. Chen X.P., Yang W.Y., Bu S., Xiao J.Z., Liu X.L., Wang N., and Zhao W.H. Effects of rosiglitazone and metformin on insulin resistance in high-fat diet rats. Zhonghua Nei Ke Za Zhi 43 4 (2004) 280-283
9. Colwell J.A. Aspirin therapy in diabetes is underutilized. Diabetes Care 24 (2001) 195-196
10. Contreras I., Reiser K.M., Martinez N., Giansante E., Lopez T., Suarez N., Postalian S., Molina M., Gonzalez F., Sanchez M.R., Camejo M., and Blanco M.C. Effects of aspirin or basic amino acids on collagen cross-links and complications in NIDDM. Diabetes Care 20 5 (1997) 832-835
11. Cook D., and Taborsky G.J.R. B-cell function and insulin secretion. In: Rifkin H., and Porte Jr. D. (Eds). Ellenberg and Rifkin's Diabetes mellitus, theory and practice. 4th edition (1996), Elsevier Science Publishing Co 89-103
12. Dandona P., Aljada A., and Bandyopadhyay A. Inflammation: The link between insulin resistance, obesity and diabetes. Trends in Immunology 25 1 (2004) 4-7
13. Diamant M., and Heine R.J. Thiazolidinediones in type 2 diabetes mellitus: Current clinical evidence. Drugs 63 13 (2003) 1373-1405
14. Eccles M., Freemantle N., and Mason J. North of England evidence based guideline development project: Guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. BMJ 316 (1998) 1303-1309
15. Evans J.L., Goldfine I.D., Maddux B.A., and Grodsky G.M. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction?. Diabetes 52 (2003) 1-8
16. Fujimoto W.Y. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. American Journal of Medicine 108 suppl (2000) 9-14
17. Gabir M.M., Hanson R.L., Debelea D., Imperatore G., Roumain J., Bennett P.H., and Knowler W.C. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 23 (2002) 1108-1112
18. Gao Z., Zuberi A., Quon M.J., Dong Z., and Ye J. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in tumor necrosis factor-treated cells through targeting multiple serine kinases. Journal of Biological Chemistry 278 27 (2003) 24944-24950
19. Garg R., Tripathy D., and Dandona P.S. Insulin resistance as a proinflammatory state: Mechanisms, mediators, and therapeutic interventions. Curr Drug Targets 4 6 (2003) 487-492
20. Gee M.K., Zhang L., Rankin S.E., Collins J.N., Kauffman R.F., and Wanger J.D. Rosiglitazone treatment improves insulin regulation and dyslipidemia in type 2 diabetic cynomolgus monkeys. Metabolism 53 9 (2004) 1121-1125
21. Giugliano D., Ceriello A., Saccomanno F., Quatraro A., Paolisso G., and D'Onofrio F. Effects of salicylate, tolbutamide, and prostaglandin E2 on insulin responses to glucose in noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 61 1 (1985) 160-166
22. Goldstein B.J., Cobitz A.R., Hand L.M., and Chen H. Are the metabolic effects of rosiglitazone influenced by baseline glycaemic control?. Current Medical Research and Opinion 19 3 (2003) 192
23. Haffner S.M., Greenberg A.S., Weston W.M., Chen H., Williams K., and Freed M.I. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 106 (2002) 679-684
24. Hundal R.S., Petersen K.F., Mayerson A.B., Randhawa P.S., Inzucchi S., Shoelson S.E., and Shulman G.I. Mechanism by which high dose aspirin improves glucose metabolism in type 2 diabetes. Journal of Clinical Investigation 109 (2002) 1321-1326
25. Itaya K. Amore sensitive and stable colorimetric determination of free fatty acids in blood. Journal of Lipid Research 18 (1977) 663-665
26. Jayagopal V., Kilpatrick E.S., Jennings P.E., Hepburn D.A., and Atkin S.L. Biological variation of homeostasis model assessment-derived insulin resistance in type 2 diabetes. Diabetes Care 25 (2003) 2022-2025
27. Jiang G., Dallas-Yang Q., Liu F., Moller D.E., and Zhang B.B. Salicylic acid reverses phorbol 12-myristate-13-acetate (PMA)- and tumor necrosis factor-α (TNF-α) induced insulin receptor substrate 1 (IRS1) serine 307 phosphorylation and insulin resistance in human embryonic kidney 293 (HEK293) cells. Journal of Biological Chemistry 278 1 (2003) 180-186
28. Katsuki A., Sumida Y., Murashima S., Murata K., Takarada Y., Ito K., Fujii M., Tsuchihashi K., Goto H., Nakatani K., and Yano Y. Serum levels of tumor necrosis factor-α are increased in obese patients with noninsulin-dependent diabetes mellitus. Journal of Clinical Endocrinology and Metabolism 83 (1998) 859-862
29. Laakso M. How good a marker is insulin level for insulin resistance?. Am J Epidemiol 137 (1993) 959-965
30. Laws A., Hoen H.M., Selby J.V., Saad M.F., Haffner S.M., and Howard B.V. Differences in insulin suppression of free fatty acid levels by gender and glucose tolerance status. Relation to plasma triglyceride and apolipoprotein B concentrations. Insulin Resistance Atherosclerosis Study (IRAS) Investigators. Arteriosclerosis, Thrombosis, and Vascular Biology 17 (1997) 64-71
31. Leinonen E., Hurt-Camejo E., Wiklund O., Hultén L.M., Hiukka A., and Taskinen M.R. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 166 (2003) 387-394
32. Lewis G.F., Carpentier A., Adeli K., and Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 23 2 (2002) 201-229
33. Lewis G.F., O'Meara N.M., Soltys P.A., Blackman J.D., Iverius P.H., Pugh W.L., Getz G.S., and Polonsky K.S. Fasting hypertriglyceridemia in noninsulin-dependent diabetes mellitus is an important predictor of postprandial lipid and lipoprotein abnormalities. Journal of Clinical Endocrinology and Metabolism 72 (1991) 934-944
34. Lobner K., and Fuchtenbusch M., (2004): Inflammation and diabetes. MMW Fortschr Med. 146(35-36):32-3, 35-6.
35. Marx N., Froehlich J., Siam L., Ittner J., Wierse G., Schmidt A., Scharnagl H., Hombach V., and Koenig W. Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arteriosclerosis, Thrombosis, and Vascular Biology 23 (2003) 283-288
36. Mata-Segreda J.F., Fernandez-Azofeifa E., Madrigal X., and Morales A.C. Clinical evaluation of acetylsalicylic acid to improve glycemia in type II diabetic patients. Acta Physiologica et Pharmacologica Latinoamericana 39 1 (1989) 9-13
37. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clinical Therapeutics 26 2 (2004) 177-190
38. Miyazaki Y., Glass L., Triplitt C., Matsuda M., Cusi K., Mahankali A., Mahankali S., Mandarino L.J., and DeFronzo R.A. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 44 (2001) 2210-2219
39. Modzelewski B., and Janiak A. Pentoxiyphilline as a cyclooxygenase (cox-2) inhibitor in experimental sepsis. Medical Science Monitor 10 7 (2004) BR233-BR237
40. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., Al-Haddad W., Dhindsa S., and Dandona P. Evidence for a potent antiinflammatory effect of rosiglitazone. Journal of Clinical Endocrinology and Metabolism 89 6 (2004) 2728-2735
41. Mora S., and Pessin J.E. An adipocentric view of signaling and intracellular trafficking. Diabetes Metabolism Research and Reviews 18 (2002) 345-356
42. Nilsson J., Jovinge S., Neimann A., Reneland R., and Lithell H. Relation between tumor necrosis factor- and insulin sensitivity in elderly men with non-insulin-dependent diabetes mellitus. Arteriosclerosis, Thrombosis, and Vascular Biology 18 (1998) 1199-1202
43. Nowak S.N., and Jaber L.A. Aspirin dose for prevention of cardiovascular disease in diabetics. Annals of Pharmacotherapy 37 1 (2003) 116-121
44. Pankow J.S., Duncan B.B., Schmidt M.I., Ballantyne C.M., Couper D.J., Hoogeveen R.C., and Golden S.H. Fasting plasma free fatty acids and risk of type 2 diabetes. Diabetes Care 27 (2004) 77-82
45. Patumraj S., Tewit S., Amatyakul S., Jariyapongskul A., Maneesri S., Kasantikul V., and Shepro D. Comparative effects of garlic and aspirin on diabetic cardiovascular complications. Drug Delivery 7 2 (2000) 91-96
46. Pershadsingh H.A. Peroxisome proliferator-activated receptor-gamma: therapeutic target for diseases beyond diabetes: quo vadis?. Expert Opinion on Investigational Drugs 13 3 (2004) 215-228
47. Pickavance L.C., Tadayyon M., Widdowson P.S., Buckingham R.E., and Wilding J.P. Therapeutic index for rosiglitazone in dietary obese rats: separation of efficacy and haemodilution. BJP 3 3 (1999) 171-180
48. Pickup J.C. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 27 (2004) 813-823
49. Pickup J.C., Chusney G.C., Thomas S.M., and Burt D. Plasma interleukin-6, tumor necrosis factor alpha and blood cytokine production in types 2 diabetes. Life Science 67 (2000) 291-300
50. Polonsky K.S., Given B.D., Hirsch L., Shapiro E.T., Tillil H., Beebe C., Galloway J.A., Frank B.H., Karrison T., and Van Cauter E. Quantitative study of insulin secretion and clearance in normal and obese subjects. Journal of Clinical Investigation 81 (1988) 435-441
51. Reaven G.M., Hollenbeck C., Jeng C.Y., Wu M.S., and Chen Y.D. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 h in patients with NIDDM. Diabetes 37 (1988) 1020-1024
52. Reaves W.G. Insulin antibody determination in theoretical and practical considerations. Diabetologia 24 (1983) 399-403
53. Rebrin K., Steil G.M., Getty L., and Bergman G.M. Free fatty acid as a link in the regulation of hepatic glucose output by peripheral insulin. Diabetes 44 9 (1995) 1038-1045
54. Richardson A.P., and Tayek J.A. Type 2 diabetic patients may have a mild form of an injury response: a clinical research center study. Am J Physiol 282 (2002) E1286-E1290
55. Ridker P.M., Hennekens C.H., Buring J.E., and Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 342 (2000) 836-843
56. Rolka D.B., Fagot-Campagna A., and Narayan K.M.V. Aspirin use among adults with diabetes. Estimates from the third national health and nutrition examination survey. Diabetes Care 24 (2001) 197-201
57. Saad M.F., Knowler W.C., Pettitt D.J., Nelson R.G., Mott D.M., and Bennett P.H. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet 1 (1989) 1356-1359
58. Senn J.J., Klover P.J., Nowak I.A., and Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 51 (2002) 3391-3399
59. Spranger J., Kroke A., Mohlig M., Hoffmann K., Bergmann M.M., Ristow M., Boeing H., and Pfeiffer A.F.H. Inflammatory cytokines and the risk to develop type 2 diabetes. Results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52 (2003) 812-817
60. Tanaka T., Itoh H., Doi K., Fukunaga K., Shintani M., Yamashita J., Chun T.H., Inoue M., Masatsugu K., Sawada N., Saito T., Nishimura H., Yoshimasa Y., and Nakao K. Down regulation of peroxisome proliferator-activated receptor γ expression by inflammatory cytokines and its reversal by thiazolidinedione. Diabetologia 42 (1999) 702-710
61. Temelkova-Kurktschiev T., Siegert G., Bergmann S., Henkel E., Koehler C., Jaross W., and Hanefield M. Subclinical inflammation is strongly related to insulin resistance but not insulin secretion in a high risk population for diabetes. Metabolism 51 (2002) 743-749
62. Thomas T., Nadackal G.T., and Thomas K. Aspirin and diabetes: inhibition of amylin aggregation by nonsteroidal anti-inflammatory drugs. Experimental and Clinical Endocrinology & Diabetes 111 1 (2003) 8-11
63. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 44 (1995) 863-870
64. Wellen K.E., and Hotamisligil G.S. Obesity-induced inflammatory changes in adipose tissue. Journal of Clinical Investigation 112 12 (2003) 1785-1788
65. Winkler G., Salamon F., Salamon D., Speer G., Simon K., and Cseh K. Elevated tumour necrosis factor alpha levels can contribute to the insulin resistance in type II (non-insulin-dependent) diabetes and obesity. Diabetologia 41 (1998) 860-862
66. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., Sole J., Nichols A., Ross J.S., Tartaglia L.A., and Chen H. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Journal of Clinical Investigation 112 12 (2003) 1821-1830
67. Yin M.J., Yamamoro Y., and Gaynon R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IKB kinase. Nature 396 (1998) 77-80
68. Yki-Jarvinen H. Pathogenesis of non-insulin-dependent diabetes mellitus. Lancet 343 (1994) 91-95
69. Yki-Jarvinen H. Thiazolidinediones. Drug Therapeutics 351 11 (2004) 1106-1118
70. Yoo J.Y., and Desiderio S. Innate and acquired immunity intersect in a global view of the acute-phase response. Proc Natl Acad Sci U S A 100 (2003) 1157-1162
71. Yuan M., Konstantopoulos N., Lee J., Hansen L., Li Z.W., Karin M., and Shoelson S.E. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikk(beta). Science 293 5535 (2001) 1673-1677
72. Zhang F., Ye C., Li G., Ding W., Zhou W., Zhu H., Chen G., Luo T., Guang M Liu Y., Zhang D., Zheng S., Yang J., Gu Y., Xie X., and Luo M. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Experimental Animmals 52 5 (2003) 401-407
73. Zhang L., Yu J., Li D., Huang Y., Chen Z., and Wang X. Effects of cytokines on carbon tetrachloride-induced hepatic fibrogenesis in rats. World Journal of Gastroenterology 10 1 (2004) 77-81